Dr Kashyap Patel: Biosimilars and Value
Kashyap Patel, MD, medical oncologist at Carolina Blood and Cancer Care, discusses the value that biosimilars bring to the health system.
Transcript:
What value do biosimilars bring to our healthcare system?
The first thing we have to do is to educate providers, payers, and patients, about what biosimilars are and what the benefits are. One clear benefit we see for the payer is the cost savings. To the patients, it’s their out-of-pocket costs; if the patient has to pay 20% out of pocket, for the cost of care, biosimilars will definitely reduce their out-of-pocket costs when they are used. For the providers, of course, if you’re in the alternate payment model space, and if you have an alternative that is equally effective and less expensive, it helps me to bring down my top price.
So in the European experience, you go back to Sweden and England, the health systems increased uptake and utilization of biosimilars, which indicates that when the price goes down, the access improves. This is very obviously starting the financial toxicity model. So biosimilars do have a place in improving access to drugs as well.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings
November 15th 2023In part 2 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® explores a cost-effectiveness analysis evaluating the use of subcutaneous trastuzumab biosimilars to treat breast cancer in a French hospital setting.
